$ARNA Headlines Arena shares surge as marketer doubles

New Post Public Reply Private Reply Replies (0) Message Board

Nov 8, 2013 at 6:23 PM

$ARNA Headlines

Arena shares surge as marketer doubles sales force for diet drug 11:41 a.m. Oct. 15, 2013 - Russ Britt
Obesity drug makers jockey for position as analysts praise Vivus 12:06 p.m. Oct. 3, 2013 - Russ Britt
Hedge funds are buying these stocks right now 1:46 p.m. July 23, 2013 - Insider Monkey
5 stocks insiders are buying 1:52 p.m. June 7, 2013 - Insider Monkey
6 gut checks before the stock market's opening bell 6:47 a.m. March 7, 2013 - Shawn Langlois
Stocks to watch Monday: Transocean, Stratasys 9:22 a.m. March 4, 2013 - Sue Chang
Arena Pharmaceuticals down 7.4% in premarket 9:11 a.m. Jan. 22, 2013 - Steve Gelsi
What 2012’s winners and losers say about 2013 6:00 a.m. Dec. 14, 2012 - Howard Gold
6 gut checks before the stock market's opening bell 6:50 a.m. Dec. 12, 2012 - Shawn Langlois
4 charts challenging resistance 7:06 a.m. Oct. 16, 2012 - The Trading Deck
Vivus sees EU regulators rejecting diet drug 12:16 p.m. Sept. 21, 2012 - MarketWatch.com
Vivus falls 11% on EU drug approval update 11:07 a.m. Sept. 21, 2012 - Val Brickates Kennedy
Arena rises as Vivus sees anti-obesity setback 7:49 a.m. Sept. 21, 2012 - Greg Morcroft
Vivus says Europe likely to reject obesity drug 7:33 a.m. Sept. 21, 2012 - MarketWatch.com
Orexigen soars 19% on analyst buy rating 12:46 p.m. Sept. 6, 2012 - Val Brickates Kennedy
Arena jumps 12% amid takeover speculation 1:55 p.m. Aug. 14, 2012 - Val Brickates Kennedy
Arena trips Nasdaq short-sale circuit breaker 3:01 p.m. Aug. 1, 2012 - Val Brickates Kennedy
Arena Pharma share drop trips short-sale limit 2:16 p.m. Aug. 1, 2012 - Laura Mandaro
Eisai gears up for launch of Arena's diet drug 9:32 a.m. July 30, 2012 - Val Brickates Kennedy
Apple, Arena active; Lumber Liquidators at new high 9:06 a.m. July 25, 2012 - blogs.marketwatch.com

Arena Pharma Q3 Loss Narrower than Expected - Analyst Blog 5:00 p.m. Today - Zacks.com
U.S. Judge Orders Ex-Morgan Staney Adviser to Return Data and 2 Heavily Traded Stocks to Follow 3:59 p.m. Today - Wall St. Cheat Sheet
VIVUS Loss In Line with Ests, Shares Fall - Analyst Blog 4:45 p.m. Nov. 7, 2013 - Zacks.com
Arena Pharmaceuticals, Eisai Expand Marketing and Supply Agreement for BELVIQ 3:03 p.m. Nov. 7, 2013 - benzinga.com
Arena's Belviq Refills - Week 20 12:43 a.m. Nov. 5, 2013 - Seeking Alpha
Arena Pharmaceuticals - Belviq OTC? 3:09 a.m. Nov. 4, 2013 - Seeking Alpha
Arena's Belviq - Week 20 Sales Data 1:28 p.m. Nov. 1, 2013 - Seeking Alpha
Arena Stock Reacts To Eisai Quarterly Call 10:26 a.m. Nov. 1, 2013 - Seeking Alpha
Should You Worry About the Short Interest in Arena Pharmaceuticals, Inc. (ARNA)? - Tale of the Tape 9:59 a.m. Nov. 1, 2013 - Zacks.com
Benzinga's Top #PreMarket Losers 7:13 a.m. Nov. 1, 2013 - benzinga.com
Uh Oh Arena Pharma! Q3 Belviq Sales Just $4.8M 7:09 a.m. Nov. 1, 2013 - TheStreet.com
A Look Back At Biotech Short Picks 2:18 p.m. Oct. 31, 2013 - Seeking Alpha
Interesting ARNA Put And Call Options For December 6th 10:46 a.m. Oct. 31, 2013 - TheStreet.com
Arena's Belviq Refills Week 19 3:29 a.m. Oct. 30, 2013 - Seeking Alpha
Latent Disconnect Between Arena's Fundamentals And Valuation 3:33 p.m. Oct. 29, 2013 - Seeking Alpha
Arena's Belviq Sales: Week 19 11:19 a.m. Oct. 25, 2013 - Seeking Alpha
November 29th Options Now Available For Arena Pharmaceuticals (ARNA) 11:15 a.m. Oct. 24, 2013 - TheStreet.com
Arena's Belviq Refills - Week 18 Data 4:26 p.m. Oct. 22, 2013 - Seeking Alpha
Arena's Belviq Sales Flat - Equity Holds 11:11 a.m. Oct. 18, 2013 - Seeking Alpha
Arena Pharmaceuticals, Inc. Enters Oversold Territory - Tale of the Tape 6:01 a.m. Oct. 18, 2013 - Zacks.com

Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results 4:10 p.m. Nov. 7, 2013 - PR Newswire
Arena Pharmaceuticals and Eisai Expand Marketing and Supply Agreement for BELVIQ® (lorcaserin HCl) to Include Most Countries Worldwide 4:02 p.m. Nov. 7, 2013 - PR Newswire
FDA Approvals, Successful Product Launches, Upcoming Earnings Schedules and Quarterly Financial Results - Research Report on Pfizer, Mettler-Toledo, Arena, Wright Medical, and Ophthotech 8:00 a.m. Nov. 7, 2013 - PR Newswire
Must Watch Stock News: Arena Pharmaceuticals, Hewlett-Packard Company, Resorts International, Alpha Natural Resources, Chevron Corporation 1:56 p.m. Nov. 4, 2013 - PR Newswire
Pre-Market Review: Arena Pharma Inc., Geron Corp., Incyte Corp. Ltd, and Spectrum Pharma Inc. 9:00 a.m. Oct. 31, 2013 - PR Newswire
Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, November 7 8:00 a.m. Oct. 30, 2013 - PR Newswire
Sales Strategies, Upcoming Financial Results Schedules, Clinical Study Updates, and FDA Agreements - Research Report on Arena, Seattle Genetics, Halozyme, Insmed, and Omeros 8:00 a.m. Oct. 21, 2013 - PR Newswire
Arena Pharmaceuticals Reports That Eisai Will Double BELVIQ® (lorcaserin HCl) CIV Sales Force by December 9:03 a.m. Oct. 15, 2013 - PR Newswire
Early Briefing and Review: Arena Pharma Inc., Spectrum Pharma Inc., Incyte Corp. Ltd., and Geron Corp. 9:26 a.m. Oct. 8, 2013 - PR Newswire
Drug Approvals, Data Presentations, Conferences, Increased Funding, and Merger Agreements - Research Report on Theravance, Arena, Exelixis, Verenium, and Enanta 8:00 a.m. Sept. 25, 2013 - PR Newswire
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 8:00 a.m. Sept. 23, 2013 - PR Newswire
Arena Pharmaceuticals to Present Clinical Data for BELVIQ® (lorcaserin HCl) CIV at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) 8:00 a.m. Sept. 18, 2013 - PR Newswire
Arena Pharmaceuticals Provides Update as Eisai's Launch of BELVIQ® (lorcaserin HCl) CIV Enters Consumer Phase 8:00 a.m. Sept. 16, 2013 - PR Newswire
Track Insider Trading in Facebook, Zynga, Arena Pharmaceuticals, Lululemon Athletica, Weatherford International, and Bank of America 8:55 a.m. Sept. 13, 2013 - PR Newswire
Wall Street Fundamentals Releases New In-Depth Stock Reports on ARIA, ARNA, EXEL and OREX 9:05 a.m. Sept. 11, 2013 - ACCESSWIRE
Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch Global Healthcare Conference 8:00 a.m. Sept. 6, 2013 - PR Newswire
Successful Clinical Trials, Data Presentations, Promising Studies, Fulfilled Agreements and Investors Conferences - Research Report on Arena, BioMarin, Clovis Oncology, MannKind, and Medivation 8:00 a.m. Sept. 3, 2013 - PR Newswire
Five Star Equities Issues New Research Reports on ARNA, COCO, CWST and GES 8:40 a.m. Aug. 30, 2013 - ACCESSWIRE
Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension 8:00 a.m. Aug. 28, 2013 - PR Newswire
Innovus Pharma Provides Corporate Update 6:30 a.m. Aug. 19, 2013 - GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Red-Eye Flights Surge, Driven By Western U.S. Routes

You can always count on some things staying the same, right? Well, if you thought red-eye flights were going to fade away, think again. These late-night wonders are not just hanging around—they're booming in the west like there's no tomorrow. Literally. Champion Traveler has laid it all out for us: about 115,580 overnight flights in 2025, a record high since this mad...

Veteran Marketer Joins The Wisory's Advisory Board

Tyrrell Schmidt Joins The Wisory's Board Out of the blue, The Wisory has snatched Tyrrell Schmidt right off the retirement bench. This doesn't seem like just another board seating; it smells like a calculated power play. Schmidt, fresh from her heavyweight stint as Global CMO at TD Bank, adds a spicy dose of marketing prowess to The Wisory's already loaded Advisory Board....

Atli Launches: AI-Powered eSIM Revolutionizes Travel

What's New in Travel Tech: Atli's Debut Wandering the globe might sound romantic until you realize your phone's a paperweight without the right data. Enter Atli, a shiny new AI-powered travel eSIM service, snugged right into your WhatsApp. This marvel comes from the folks at XForge Mobile and aims to obliterate the hassle of getting connected abroad. You know those...

Rare Collectibles Highlight Morphy's Auction on Oct 4

Anticipation Builds for Morphy's Auction Event Morphy's upcoming event on October 4th is all about tapping into the era of revved engines, gleaming gasoline signs, and some history that could put Hollywood tales to shame. The auction isn't just a stroll down memory lane; it features over 650 lots, each a time capsule of America's automotive past. From Al Capone's ritzy...

K-9 Hero Act Aims to Ease Costs for Retired Dogs' Care

Let's Talk About the Loyalty that Dogs Deserve Who would've thought we'd be chatting about our four-legged heroes in a federal setting? But here we are, giving well-deserved attention to those furry federal agents. They're the ones who sniff out bombs and tackle crooks, and they're not asking for a retirement plan with a yacht – just some vet care! What the K-9 Hero Act...

AbbVie's Bold Leap in Menstrual Migraine Treatment

AbbVie's Game-Changing Atogepant Study When it comes to pushing boundaries in the pharmaceutical world, there's no sitting on the fence. AbbVie's Phase 3 LUNA study results are painting a bright picture for women who suffer from the relentless grip of menstrual migraines. In a world where not a single treatment option has been approved specifically for this condition,...

CrossCountry Mortgage Boosts Loan Limits, Flexibility for 2027

Trailblazing in the Mortgage Game Well, what do we have here? CrossCountry Mortgage, the big cheese of retail mortgage lenders, is cranking up their conforming loan limits to a hefty $845,000. They're jumping the gun on the Federal Housing Finance Agency's official 2027 announcement. It's a classic move—proactive, bold, and a bit of a gamble, if you ask me. They’re...

RTI's $14M Boost: A Game-Changer for Tech Innovators

Breaking Ground in Tech Deployment The march toward commercializing new tech can be a nightmare. Ask any innovator trying to leap from lab genius to market ready, and they'll tell you the pathway is paved with hurdles—especially in the rough-and-tumble world of energy and industrial tech. RTI International's latest $14 million move? That's a massive step in leveling the...

Havoc, CSBC Partner for Autonomous Maritime Future

A Strategic Move Across the Pacific Well, folks, in an era where the seas aren't just blue but powered by tech-backed autonomy, here's a new chapter—the kind that doesn't just hint at innovation, it screams it. Havoc, that crafty leader in all things autonomous, inked a game-changing deal with Taiwan's shipbuilding behemoth, CSBC Corporation. They're not just building...

Moore Law Investigates Aardvark Therapeutics' Risks

Moore Law Launches Probe Into Aardvark Therapeutics Nobody likes stumbling across bad news over their morning coffee, but sometimes the market loves to keep you on your toes. Now it's Aardvark Therapeutics (NASDAQ: AARD) in the headlines, and not how they'd like. This time, Moore Law PLLC is rolling up its sleeves to dig into potential misconduct by the company's top...